Carlos L. Arteaga, M.D., a devoted cancer researcher and clinician, was named Director of the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center in September 2017. He also serves as Associate Dean of Oncology Programs. Dr. Arteaga is internationally recognized for his work in laboratory-based translational research and advancing the care of breast cancer patients. The majority of Dr. Arteaga’s career has been as a physician-scientist in Medical Oncology at the Vanderbilt-Ingram Cancer Center of Vanderbilt University, where he served as Associate Director for Translational/Clinical Research and Director of the Center for Cancer Targeted Therapies. At Vanderbilt, he also led a successful translational research program that includes a National Cancer Institute/National Institutes of Health SPORE award in breast cancer. He is a member of the American Society for Clinical Investigation and the Association of American Physicians. He has earned numerous accolades from the American Cancer Society, the American Association for Cancer Research (AACR), Susan G. Komen for the Cure Foundation, and the American Society of Clinical Oncology. A former President of the AACR, he serves on the boards of advisors of several cancer centers and breast cancer programs. Dr. Arteaga earned his medical degree from Facultad de Ciencias Médicas at the Universidad de Guayaquil in Ecuador. He trained in Internal Medicine at Emory University and in Medical Oncology at the University of Texas Health Science Center at San Antonio.
- Medical School
- Universidad de Guayaquil, Ecuador (1980)
- Emory University School of Medicine (1984), Internal Medicine
- University of Texas Health Science Center, San Antonio (1988), Hematology Oncology
- Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel.
- Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W Oncologist 2014 Jun 19 6 616-22
- Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
- Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y, Cantley LC, Winer E, Arteaga CL J. Clin. Oncol. 2014 Apr 32 12 1202-9
- Emergence of constitutively active estrogen receptor-a mutations in pretreated advanced estrogen receptor-positive breast cancer.
- Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, Ferrer-Lozano J, Perez-Fidalgo JA, Cristofanilli M, Gómez H, Arteaga CL, Giltnane J, Balko JM, Cronin MT, Jarosz M, Sun J, Hawryluk M, Lipson D, Otto G, Ross JS, Dvir A, Soussan-Gutman L, Wolf I, Rubinek T, Gilmore L, Schnitt S, Come SE, Pusztai L, Stephens P, Brown M, Miller VA Clin. Cancer Res. 2014 Apr 20 7 1757-1767
- ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.
- Arteaga CL, Engelman JA Cancer Cell 2014 Mar 25 3 282-303
- Heart failure and breast cancer therapies: moving towards personalized risk assessment.
- Francis SA, Cheng S, Arteaga CL, Moslehi J J Am Heart Assoc 2014 Feb 3 1 e000780
- Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.
- Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ, Arteaga CL Cancer Discov 2014 Feb 4 2 232-45
- Evaluating HER2 amplification status and acquired drug resistance in breast cancer cells using Raman spectroscopy.
- Bi X, Rexer B, Arteaga CL, Guo M, Mahadevan-Jansen A J Biomed Opt 2014 Feb 19 2 025001
- Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
- Rexer BN, Chanthaphaychith S, Dahlman K, Arteaga CL Breast Cancer Res. 2014 Jan 16 1 R9
- Outsmarting cancer: the power of hybrid genomic/proteomic biomarkers to predict drug response.
- Rexer BN, Arteaga CL Breast Cancer Res. 2014 16 2 303
- Progress in breast cancer: overview.
- Arteaga CL Clin. Cancer Res. 2013 Dec 19 23 6353-9